Pro-inflammatory cytokinemia is frequently found in Down syndrome patients with hematological disorders

Leukemia Research

Volumn 31, Issue 9, 2007, Pages 1199-1203

  Shimada, Akira ^a   Hayashi, Yasuhide ^a   Ogasawara, Mizuho ^a   Park, Myoung ja ^a   Katoh, Masahiko ^a   Minakami, Hisanori ^b   Kitoh, Toshiyuki ^c   Kojima, Seiji ^d   Kawa, Keisei ^e   Kimura, Hirokazu ^f  

^a Gunma Children's Medical Center   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SHIGA MEDICAL CENTER FOR CHILDREN   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

^e RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^f GUNMA PREFECTURAL INSTITUTE OF PUBLIC HEALTH AND ENVIRONMENTAL SCIENCES   (Japan)

Author keywords

Acute megakaryoblastic leukaemia; Down syndrome; Pro inflammatory cytokine; Transient abnormal myelopoiesis

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN SYNDROME; FLUORESCENCE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; PATHOGENESIS; PRIORITY JOURNAL; TRANSIENT ABNORMAL MYELOPOIESIS; ACUTE NONLYMPHOCYTIC LEUKEMIA; BLOOD; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; INFANT; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEWBORN; PRESCHOOL CHILD;

CHILD, PRESCHOOL; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; DOWN SYNDROME; HEMATOLOGIC DISEASES; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; MYELODYSPLASTIC SYNDROMES; MYELOFIBROSIS;

EID: 34249898927     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.09.008     Document Type: Article

References (44)

1. Scotese I., Gaetaniello L., Matarese G., Lecora M., Racioppi L., and Pignata C. T cell activation deficiency associated with an aberrant pattern of protein tyrosine phosphorylation after CD3 perturbation in Down's syndrome. Pediatr Res 44 (1998) 252-258
2. Tuysuz B., and Beker D.B. Thyroid dysfunction in children with Down's syndrome. Acta Paediatr 90 (2001) 1389-1393
3. Cuadrado E., and Barrena M.J. Immune dysfunction in Down's syndrome: primary immune deficiency or early senescence of the immune system?. Clin Immunol Immunopathol 78 (1996) 209-214
4. Murphy M., and Epstein L.B. Down syndrome [DS] peripheral blood contains phenotypically mature CD3 + TCR alpha, beta+ cells but abnormal proportions of TCR alpha, beta+, TCR gamma, delta+, and CD4+ CD45RA+ cells: evidence for an inefficient release of mature T cells by the DS thymus. Clin Immunol Immunopathol 62 (1992) 245-251
5. Peled-Kamar M., Lotem J., Okon E., Sachs L., and Groner Y. Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn-superoxide dismutase: implications for Down syndrome. EMBO J 14 (1995) 4985-4993
6. de Hingh Y.C., van der Vossen P.W., Gemen E.F., Mulder A.B., Hop W.C., Brus F., et al. Intrinsic abnormalities of lymphocyte counts in children with Down syndrome. J Pediatr 147 (2005) 744-747
7. Franciotta D., Verri A., Zardini E., Andreoni L., De Amici M., Moratti R., et al. Interferon-gamma- and interleukin-4-producing T cells in Down's syndrome. Neurosci Lett 395 (2006) 67-70
8. Kalman J., Juhasz A., Laird G., Dickens P., Jardanhazy T., Rimanoczy A., et al. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease. Acta Neurol Scand 96 (1997) 236-240
9. Griffin W.S., and Mrak R.E. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol 72 (2002) 233-238
10. Carta M.G., Serra P., Ghiani A., Manca E., Hardoy M.C., Del Giacco G.S., et al. Chemokines and pro-inflammatory cytokines in Down's syndrome: an early marker for Alzheimer-type dementia?. Psychother Psychosom 71 (2002) 233-236
11. Mrak R.E., and Griffin W.S. Trisomy 21 and the brain. J Neuropathol Exp Neurol 63 (2004) 679-685
12. Martin G.M. Syndromes of accelerated aging. Natl Cancer Inst Monogr 60 (1982) 241-247
13. Hayashi Y., Eguchi M., Sugita K., Nakazawa S., Sato T., Kojima S., et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood 72 (1988) 15-23
14. Webb D.K. Optimizing therapy for myeloid disorders of Down syndrome. Br J Haematol 131 (2005) 3-7
15. Hitzler J.K., and Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 5 (2005) 11-20
16. Al-Kasim F., Doyle J.J., Massey G.V., Weinstein H.J., and Zipursky A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol 24 (2002) 9-13
17. Dormann S., Kruger M., Hentschel R., Rasenack R., Strahm B., Kontny U., et al. Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome. Eur J Pediatr 163 (2004) 374-377
18. Massey G.V., Zipursky A., Chang M.N., Doyle J.J., Nasim S., Taub J.W., et al. A prospective study of the natural history of transient leukemia (TL) in neonates with down syndrome (DS): a children's oncology group (COG) study POG-9481. Blood 107 (2006) 4606-4613
19. Shimada A., Maruyama K., Shitara T., Kato M., Cho K., Kobayashi T., et al. Pro-inflammatory cytokinemia associated with transient myeloproliferative disorder in Down syndrome. Biol Neonate 85 (2004) 167-172
20. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
21. Nagao T., Lampkin B.C., and Hug G. A neonate with Down's syndrome and transient abnormal myelopoiesis: serial blood and bone marrow studies. Blood 36 (1970) 443-447
22. Fulton R.J., McDade R.L., Smith P.L., Kienker L.J., and Kettman Jr. J.R. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 43 (1997) 1749-1756
23. Prabhakar U., Eirikis E., Reddy M., Silvestro E., Spitz S., Pendley II C., et al. Validation and comparative analysis of a multiplexed assay for the simultaneous quantitative measurement of Th1/Th2 cytokines in human serum and human peripheral blood mononuclear cell culture supernatants. J Immunol Methods 291 (2004) 27-38
24. Murphy M., Hyun W., Hunte B., Levine A.D., and Epstein L.B. A role for tumor necrosis factor-alpha and interferon-gamma in the regulation of interleukin-4-induced human thymocyte proliferation in vitro. Heightened sensitivity in the Down syndrome (trisomy 21) thymus. Pediatr Res 32 (1992) 269-276
25. Bar-Peled O., Korkotian E., Segal M., and Groner Y. Constitutive overexpression of Cu/Zn superoxide dismutase exacerbates kainic acid-induced apoptosis of transgenic-Cu/Zn superoxide dismutase neurons. Proc Natl Acad Sci USA 93 (1996) 8530-8535
26. 2-induced DNA damage and alter its site specificity. FEBS Lett 495 (2001) 187-190
27. Patel H.C., Boutin H., and Allan S.M. Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann N Y Acad Sci 992 (2003) 39-47
28. Zihni L. Down's syndrome, interferon sensitivity and the development of leukaemia. Leuk Res 18 (1994) 1-6
29. Arai H., Ishida A., Nakajima W., Nishinomiya F., Yamazoe A., and Takada G. Immunohistochemical study on transforming growth factor-beta1 expression in liver fibrosis of Down's syndrome with transient abnormal myelopoiesis. Hum Pathol 30 (1999) 474-476
30. Hattori H., Matsuzaki A., Suminoe A., Ihara K., Nakayama H., and Hara T. High expression of platelet-derived growth factor and transforming growth factor-beta 1 in blast cells from patients with Down Syndrome suffering from transient myeloproliferative disorder and organ fibrosis. Br J Haematol 115 (2001) 472-475
31. Martyre M.C. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma 20 (1995) 39-44
32. Bataller R., and Brenner D.A. Liver fibrosis. J Clin Invest 115 (2005) 209-218
33. Allan S.M. The role of pro- and anti-inflammatory cytokines in neurodegeneration. Ann N Y Acad Sci 917 (2000) 84-93
34. Shohat B., Shohat M., Faktor J.H., Barkay G., Harell D., Kozenitzky L., et al. Soluble interleukin-2 receptor and interleukin-2 in human amniotic fluid of normal and abnormal pregnancies. Biol Neonate 63 (1993) 281-284
35. Bromage S.J., Lang A.K., Atkinson I., and Searle R.F. Abnormal TGFbeta levels in the amniotic fluid of Down syndrome pregnancies. Am J Reprod Immunol 44 (2000) 205-210
36. Shimada A., Xu G., Toki T., Kimura H., Hayashi Y., and Ito E. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Blood 103 (2004) 366
37. Zipursky A., Rose T., Skidmore M., Thorner P., and Doyle J. Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatr Hematol Oncol 13 (1996) 81-87
38. Hassan H.T., and Freund M. Characteristic biological features of human megakaryoblastic leukaemia cell lines. Leuk Res 19 (1995) 589-594
39. Komatsu N., Suda T., Moroi M., Tokuyama N., Sakata Y., Okada M., et al. Growth and differentiation of a human megakaryoblastic cell line, CMK. Blood 74 (1989) 42-48
40. Kitamura T., Tange T., Terasawa T., Chiba S., Kuwaki T., Miyagawa K., et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 140 (1989) 323-334
41. Brach M.A., Lowenberg B., Mantovani L., Schwulera U., Mertelsmann R., and Herrmann F. Interleukin-6 (IL-6) is an intermediate in IL-1-induced proliferation of leukemic human megakaryoblasts. Blood 76 (1990) 1972-1979
42. Liu R.Y., Fan C., Mitchell S., Chen Q., Wu J., and Zuckerman K.S. The role of type I and type II tumor necrosis factor [TNF] receptors in the ability of TNF-alpha to transduce a proliferative signal in the human megakaryoblastic leukemic cell line Mo7e. Cancer Res 58 (1998) 2217-2223
43. Estrov Z., Kurzrock R., and Talpaz M. Cytokines and their antagonists in myeloid disorders. Semin Hematol 32 (1995) 220-231
44. Faderl S., Harris D., Van Q., Kantarjian H.M., Talpaz M., and Estrov Z. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood 102 (2003) 630-637